The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR PERSISTENT NEW VESSELS IN DIABETIC RETINOPATHY (IBEPE STUDY)
Abstract
OBJECTIVE: To evaluate the short-term fluorescein angiographic and visual acuity effects of a single intravitreal injection of bevacizumab (Avastin) for the management of persistent new vessels (NV) associated with diabetic retinopathy. METHODS: A prospective, nonrandomized open-label study of diabetic patients with actively leaking NV refractory to laser treatment and best-corrected Early Treatment Diabetic Retinopathy Study visual acuity (BCVA) worse than 20/40. Standardized ophthalmic evaluation was performed at baseline and at weeks 1, 6, and 12 (+/-1) following intravitreal injection of 1.5 mg of bevacizumab. Main outcome measures include changes in total area of fluorescein leakage from active NV and BCVA. RESULTS: Fifteen consecutive patients (men, 9 [60%]; women, 6 [40%]) were included and all completed the 12-week follow-up period of the study. The mean +/- SD age of participants was 60.08 +/- 7.75 years (median, 59.5; range, 49-73 years). At baseline, mean +/- standard error of the mean (SEM) NV leakage area was 27.79 +/- 6.29 mm2. The mean +/- SEM area of active leaking NV decreased significantly to 5.43 +/- 2.18 mm2 and 5.50 +/- 1.24 mm2 (P < 0.05, Tukey multiple comparisons post-test) at 1 and 12 weeks postinjection, respectively; at week 6 no leakage was observed. The mean +/- SEM logMAR (Snellen equivalent) BCVA improved significantly from 0.90 (20/160) +/- 0.11 at baseline to 0.76 (20/125(+2)) +/- 0.12, 0.77 (20/125(+2)) +/- 0.11, and 0.77 (20/125(+2)) +/- 0.12 at weeks 1, 6, and 12, respectively (P < 0.05, Tukey multiple comparisons post-test). No major adverse events were observed. CONCLUSIONS: Intravitreal injection of bevacizumab achieved short-term reduction of fluorescein leakage from persistent active NV without loss of vision in patients with diabetic retinopathy. Further studies to investigate the role of anti-VEGF therapy with bevacizumab for the management of diabetic retinopathy refractory to laser treatment are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793
The Lens Opacities Classification System III
Chylack, L. T. (1993) · Archives of Ophthalmology · doi:10.1001/archopht.1993.01090060119035 · Cited by 2,913
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Kabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., Griffing, S., & Bergsland, E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,716
Adamis, A. P., Miller, J. W., Bernal, M.-T., D'Amico, D. J., Folkman, J., Yeo, T.-K., & Yeo, K.-T. (1994) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)75794-0 · Cited by 1,296
Aiello, L. P., Pierce, E. A., Foley, E. D., Takagi, H., Chen, H., Riddle, L., Ferrara, N., King, G. L., & Smith, L. E. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.23.10457 · Cited by 1,260
Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration
Avery, R. L., Pieramici, D. J., Rabena, M. D., Castellarin, A. A., Nasir, M. A., & Giust, M. J. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.11.019 · Cited by 1,133
Fundus Photographic Risk Factors for Progression of Diabetic Retinopathy
(1991) · Ophthalmology · doi:10.1016/s0161-6420(13)38014-2 · Cited by 814
MICHELS, S., ROSENFELD, P., PULIAFITO, C., MARCUS, E., & VENKATRAMAN, A. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2005.02.007 · Cited by 664
Adamis, A. P. (1996) · Archives of Ophthalmology · doi:10.1001/archopht.1996.01100130062010 · Cited by 635
Tolentino, M. J., Miller, J. W., Gragoudas, E. S., Jakobiec, F. A., Flynn, E., Chatzstefanou, K., Ferrara, N., & Adamis, A. P. (1996) · Ophthalmology · doi:10.1016/s0161-6420(96)30420-x · Cited by 518
SPAIDE, R. F., & FISHER, Y. L. (2006) · Retina · doi:10.1097/00006982-200603000-00004 · Cited by 507
Rosenfeld, P. J., Fung, A. E., & Puliafito, C. A. (2005) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/1542-8877-20050701-15 · Cited by 489
Aliello, L. P. (1995) · Medical Entomology and Zoology · Cited by 463
ITURRALDE, D., SPAIDE, R. F., MEYERLE, C. B., KLANCNIK, J. M., YANNUZZI, L. A., FISHER, Y. L., SORENSON, J., SLAKTER, J. S., FREUND, K. B., COONEY, M., et al. (2006) · Retina · doi:10.1097/00006982-200603000-00005 · Cited by 460
Malecaze, F. (1994) · Archives of Ophthalmology · doi:10.1001/archopht.1994.01090230090028 · Cited by 364
SHAHAR, J., AVERY, R. L., HEILWEIL, G., BARAK, A., ZEMEL, E., LEWIS, G. P., JOHNSON, P. T., FISHER, S. K., PERLMAN, I., & LOEWENSTEIN, A. (2006) · Retina · doi:10.1097/00006982-200603000-00002 · Cited by 350
REGRESSION OF RETINAL AND IRIS NEOVASCULARIZATION AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT
AVERY, R. L. (2006) · Retina · doi:10.1097/00006982-200603000-00016 · Cited by 342
Tolentino, M. J. (1996) · Archives of Ophthalmology · doi:10.1001/archopht.1996.01100140172010 · Cited by 332
TESTING INTRAVITREAL TOXICITY OF BEVACIZUMAB (AVASTIN)
MANZANO, R. P. A., PEYMAN, G. A., KHAN, P., & KIVILCIM, M. (2006) · Retina · doi:10.1097/00006982-200603000-00001 · Cited by 305
Tolentino, M. J., Mcleod, D. S., Taomoto, M., Otsuji, T., Adamis, A. P., & Lutty, G. A. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)01381-2 · Cited by 250
Changes in Retinal Neovascularization after Pegaptanib (Macugen) Therapy in Diabetic Individuals
(2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.10.012 · Cited by 244
Early Vitrectomy for Severe Proliferative Diabetic Retinopathy in Eyes with Useful Vision
(1988) · Ophthalmology · doi:10.1016/s0161-6420(88)33015-0 · Cited by 216
Pars Plana Vitrectomy in the Early Treatment Diabetic Retinopathy Study
Flynn, H. W., Chew, E. Y., Simons, B. D., Barton, F. B., Remaley, N. A., & Ferris, F. L. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)31779-8 · Cited by 202
ELECTROPHYSIOLOGIC FINDINGS AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT
Maturi, R. K., Bleau, L., & Wilson, D. L. (2006) · Retina · doi:10.1097/00006982-200603000-00003 · Cited by 157
Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia
Nguyen, Q. D. (2005) · British Journal of Ophthalmology · doi:10.1136/bjo.2005.066431 · Cited by 152
Bevacizumab for Patients with Metastatic Renal Cancer
Yang, J. C.-H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-050006 · Cited by 128
VANDER, J. F., Duker, J. S., Benson, W. E., Brown, G. C., McNamara, J. A., & Rosenstein, R. B. (1991) · Ophthalmology · doi:10.1016/s0161-6420(91)32085-2 · Cited by 101
Mordenti, J. J. (1999) · Toxicological Sciences · doi:10.1093/toxsci/52.1.101 · Cited by 78
Cited by
Vascular endothelial growth factor in eye disease
Penn, J. S., Madan, A., Caldwell, R. B., Bartoli, M., Caldwell, R. W., & Hartnett, M. E. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.05.001 · Cited by 762
Overview of Epidemiologic Studies of Diabetic Retinopathy
Kobrin Klein, B. E. (2007) · Ophthalmic Epidemiology · doi:10.1080/09286580701396720 · Cited by 734
Kern, T. S. (2007) · Journal of Diabetes Research · doi:10.1155/2007/95103 · Cited by 614
Pathophysiology of Diabetic Retinopathy
Tarr, J. M., Kaul, K., Chopra, M., Kohner, E. M., & Chibber, R. (2013) · ISRN Ophthalmology · doi:10.1155/2013/343560 · Cited by 455
Anti-vascular endothelial growth factor therapy for ocular neovascular disease
Andreoli, C. M., & Miller, J. W. (2007) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e3282f0ca54 · Cited by 274
Metadata
- Authors
- JORGE, R., COSTA, R. A., CALUCCI, D., CINTRA, L. P., & SCOTT, I. U.
- Venue
- Retina
- Published
- 2006-11
- Volume
- 26
- Issue
- 9
- Pages
- 1006-1013
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W2045390750
- Cited by
- 258
- References
- 34
- FWCI
- 23.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.